Dyne Therapeutics Inc (NAS:DYN)
$ 31.13 1.9 (6.5%) Market Cap: 3.17 Bil Enterprise Value: 2.28 Bil PE Ratio: 0 PB Ratio: 4.49 GF Score: 42/100

Dyne Therapeutics Inc at Chardan Genetic Medicines Conference (Virtual) Transcript

Oct 05, 2021 / 01:00PM GMT
Release Date Price: $15.74 (+0.38%)
Keay Nakae
Chardan Capital Markets - Analyst

It's my pleasure to introduce our next guest from Dyne Therapeutics, Chief Executive Officer, Josh Brom; and Chief Scientific Officer, Dr. Oxana Beskrovnaya. The format for this session is roughly a 25-minute fireside chat. (Conference Instructions). With that, Josh, Oxana, welcome. Thank you for joining us.

Questions & Answers

Keay Nakae
Chardan Capital Markets - Analyst

Josh, to start out, could you provide a couple minutes of introductory comments about Dyne for investors new to the story?

Josh Brumm
Dyne Therapeutics, Inc. - President and CEO

Yes. Thanks, Keay, I'd be happy to do it. Thanks again so much for having us today. We're excited to join you, and just want to remind everyone that during our discussion, as usual, we'll be making forward-looking statements, so please refer to our SEC filings for more information on that account.

Look, at Dyne, it all starts with our mission. Keay, as you know, we are laser-focused on muscle diseases and

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot